Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment

SIMPLE SUMMARY: Recent genomic analytical advancements have revealed that BRCA1/2 pathogenic variants are the most frequent mutations among DNA damage repair genes in prostate cancer. Polyadenosine diphosphatase ribose polymerase (PARP) inhibitor, olaparib, has been shown as an effective therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Takahiro, Sekito, Sho, Kageyama, Takumi, Sugino, Yusuke, Sasaki, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177034/
https://www.ncbi.nlm.nih.gov/pubmed/37174127
http://dx.doi.org/10.3390/cancers15092662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177034/
https://www.ncbi.nlm.nih.gov/pubmed/37174127
http://dx.doi.org/10.3390/cancers15092662

Ejemplares similares